TY - JOUR
T1 - MDM2-TP53 Crossregulation
T2 - An Underestimated Target to Promote Loss of TP53 Function and Cell Survival
AU - Soussi, T.
AU - Kroemer, G.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Half of human cancers bear inactivating mutations of the tumor suppressor gene TP53, but the other half do not. In a recent issue of Cancer Cell, Dhar et al. and Zhu et al. reported that, in liver cancer and medulloblastoma, MDM2 is constitutively activated, causing a loss of TP53 function that does not require TP53 mutation. On theoretical grounds, such cancer would be amenable to treatment with MDM2 inhibitors.
AB - Half of human cancers bear inactivating mutations of the tumor suppressor gene TP53, but the other half do not. In a recent issue of Cancer Cell, Dhar et al. and Zhu et al. reported that, in liver cancer and medulloblastoma, MDM2 is constitutively activated, causing a loss of TP53 function that does not require TP53 mutation. On theoretical grounds, such cancer would be amenable to treatment with MDM2 inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85050141121&partnerID=8YFLogxK
U2 - 10.1016/j.trecan.2018.07.001
DO - 10.1016/j.trecan.2018.07.001
M3 - Short survey
C2 - 30149877
AN - SCOPUS:85050141121
SN - 2405-8033
VL - 4
SP - 602
EP - 605
JO - Trends in Cancer
JF - Trends in Cancer
IS - 9
ER -